» Articles » PMID: 35353294

C-terminal Binding Protein 2 Promotes High-glucose-triggered Cell Proliferation, Angiogenesis and Cellular Adhesion of Human Retinal Endothelial Cell Line

Overview
Journal Int Ophthalmol
Specialty Ophthalmology
Date 2022 Mar 30
PMID 35353294
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: The proliferation and angiogenesis of human retinal endothelial cells (HRECs) are critical for the pathophysiology of diabetic retinopathy (DR). C-terminal binding protein 2 (CtBP2) has multiple biologic functions, but its effect on HRECs under high-glucose (HG) conditions is unclear.

Methods: The cell viability, angiogenesis, cellular adhesion and CtBP2 expression levels of HRECs were measured following treatment with different concentrations of glucose. Small interfering CtBP2-targeting RNA, wide-type and function mutant plasmid of CtBP2 were constructed and then were transfected into HRECs to evaluate the effects of CtBP2 on cell functions of HRECs.

Results: The expression of CtBP2 in HRECs was increased after HG treatment. HG treatment significantly increased cell proliferation, angiogenesis, and decreased relative gene expressions in gap junctions, tight junctions and adherens junctions. After CtBP2 was inhibited via siRNA, the changes induced by HG were partially restored. Conversely, only wild-type CtBP2 could increase cell proliferation and angiogenesis under HG condition. Mechanistically, we also found that CtBP2 exerted its functions to effect HG-induced changes via Akt signaling pathway.

Conclusion: This study implicates that CtBP2 promotes HG-induced cell proliferation, angiogenesis and cellular adhesion, and CtBP2 might be a potential target in the prevention of DR.

Citing Articles

C-Terminal Binding Protein: Regulator between Viral Infection and Tumorigenesis.

Huang M, Li Y, Li Y, Liu S Viruses. 2024; 16(6).

PMID: 38932279 PMC: 11209466. DOI: 10.3390/v16060988.


CTBP2 contributes to cisplatin resistance in lung adenocarcinoma by inhibiting generation of reactive oxygen species.

Wang M, Shi L, Fan S, Hu C Transl Cancer Res. 2024; 13(4):1695-1706.

PMID: 38737699 PMC: 11082667. DOI: 10.21037/tcr-23-2135.

References
1.
Shaw J, Sicree R, Zimmet P . Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2009; 87(1):4-14. DOI: 10.1016/j.diabres.2009.10.007. View

2.
Penn J, Madan A, Caldwell R, Bartoli M, Caldwell R, Hartnett M . Vascular endothelial growth factor in eye disease. Prog Retin Eye Res. 2008; 27(4):331-71. PMC: 3682685. DOI: 10.1016/j.preteyeres.2008.05.001. View

3.
Behl T, Kotwani A . Exploring the various aspects of the pathological role of vascular endothelial growth factor (VEGF) in diabetic retinopathy. Pharmacol Res. 2015; 99:137-48. DOI: 10.1016/j.phrs.2015.05.013. View

4.
Huang H, He J, Johnson D, Wei Y, Liu Y, Wang S . Deletion of placental growth factor prevents diabetic retinopathy and is associated with Akt activation and HIF1α-VEGF pathway inhibition. Diabetes. 2014; 64(1):200-12. PMC: 4274802. DOI: 10.2337/db14-0016. View

5.
Zhang Y, Jiang X, Qin X, Ye D, Yi Z, Liu M . RKTG inhibits angiogenesis by suppressing MAPK-mediated autocrine VEGF signaling and is downregulated in clear-cell renal cell carcinoma. Oncogene. 2010; 29(39):5404-15. DOI: 10.1038/onc.2010.270. View